Work

Phase I/II study of the EP4 antagonist vorbipiprant combined with anti-PD-1 immunotherapy: Safety and efficacy results in metastatic gastrointestinal non-colorectal cancers.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.2608

Authors: Filippo Pietrantonio, Giovanni Randon, Chiara Carlotta Pircher, Filippo Ghelardi, Carolina Sciortino, Sara Alessandrini, Michele Palazzo, Nadia Brambilla, Giampaolo Giacovelli, Marta Monteforte, Federica Girolami, Lucio C Rovati

Institutions: Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milan, University of Milano-Bicocca

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410805572

Cites:

Cited by:

Related to: 10